Stockreport

GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients

GeneDx Holdings Corp. - Class A  (WGS) 
PDF ultraRapid testing addresses the underutilization of testing in the NICU and can lead to more than $15K in healthcare savings per child GAITHERSBURG, Md.--(BUSINESS W [Read more]